Cipla Usa Drug Patent Portfolio
Cipla Usa owns 1 orange book drug protected by 4 US patents Given below is the list of Cipla Usa's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8383596 | Antibacterial aminoglycoside analogs | 02 Jun, 2031 | Active |
| US8822424 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
| US9266919 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
| US9688711 | Antibacterial aminoglycoside analogs | 21 Nov, 2028 | Active |
Latest Legal Activities on Cipla Usa's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cipla Usa.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US8822424 |
|
FDA Final Eligibility Letter
Critical
| 30 Jan, 2024 | US8383596 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 23 Aug, 2023 | US9266919 |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2023 | US8383596 |
| transaction for FDA Determination of Regulatory Review Period | 15 May, 2023 | US8822424 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US8383596 |
| transaction for FDA Determination of Regulatory Review Period | 18 Apr, 2023 | US8822424 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 02 Mar, 2022 | US8822424 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 28 Dec, 2020 | US9688711 |
| Second letter to regulating agency to determine regulatory review period | 24 Sep, 2020 | US8822424 |
| Second letter to regulating agency to determine regulatory review period | 24 Sep, 2020 | US8383596 |
| 7.5 yr surcharge - late pmt w/in 6 mo, Small Entity | 28 Aug, 2020 | US8383596 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 28 Aug, 2020 | US8383596 |
|
Email Notification
Critical
| 14 May, 2020 | US8822424 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 14 May, 2020 | US8383596 |
Cipla Usa's Family Patents
Cipla Usa drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 32.4% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Cipla Usa Drug List
Given below is the complete list of Cipla Usa's drugs and the patents protecting them.
1. Zemdri
Zemdri is protected by 4 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8383596 | Antibacterial aminoglycoside analogs |
02 Jun, 2031
(6 years from now)
| Active |
| US8822424 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(4 years from now)
| Active |
| US9266919 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(4 years from now)
| Active |
| US9688711 | Antibacterial aminoglycoside analogs |
21 Nov, 2028
(4 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Zemdri's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List